By Benjamin Lowentritt, MD | When a patient learns they have metastatic castration-sensitive prostate cancer (mCSPC), it often marks the beginning of a long and uncertain journey. The first conversations that follow can shape how that patient feels about their treatment and their role in it. In those early moments, how we respond matters.